Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis.

Immunotherapy 2021 Aug

filter terms:

Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.

Citation

Ekaterina Laukhtina, Keiichiro Mori, Hadi Mostafaei, Axel S Merseburger, Peter Nyirady, Marco Moschini, Fahad Quhal, Victor M Schuettfort, Benjamin Pradere, Reza Sari Motlagh, Dmitry Enikeev, Shahrokh F Shariat, European Association Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group. Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. Immunotherapy. 2021 Aug;13(11):917-929